

Title: A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with Relapsing and Remitting Multiple Sclerosis.

Authors: Coe S.^{a*}, Cossington, J.^a, Collett J.^a, Soundy A.^b, Izadi H.^a, Ovington M.^a, Durkin L.^a, Kirsten M.^a, Clegg M.^d, Cavey A.^c, Wade DT.^a, Palace J.^c, DeLuca G.^c, Chapman K.^a, Harrison JM.^a, Buckingham E.^a & Dawes H.^a

*Corresponding author: Dr Shelly Coe, ^aCentre for Movement Occupational and Rehabilitation Sciences, Oxford Brookes Centre for Nutrition and Health, Department of Sport Health Sciences and Social Work, Oxford Brookes University, Oxford, OX30BP. Email: scoe@brookes.ac.uk, Tel: +(0)1865 483839. ^bUniversity of Birmingham, Birmingham. ^cDepartment of Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK. Department of Food and Nutritional Sciences, University of Reading, Whiteknights, Reading RG6 6AP.

Key words

Fatigue, Cocoa, Diet, Multiple Sclerosis, Flavonoids

Word count: 3,335

References: 33

1 **Abstract**

2

3 The impact of flavonoids on fatigue has not been investigated in Relapsing and Remitting Multiple
4 Sclerosis (RRMS).

5

6 **Objective:** To determine the feasibility and estimate the potential effect of flavonoid-rich cocoa on
7 fatigue and fatigability in RRMS.

8

9 **Methods:** A randomised double-blind placebo-controlled feasibility study in people recently
10 diagnosed with RRMS and fatigue, throughout the Thames Valley (ISRCTN: 69897291). During a six
11 week intervention participants consumed a high or low flavonoid cocoa beverage daily. Fatigue and
12 fatigability were measured at three visits (weeks 0, 3 and 6). Feasibility and fidelity were assessed
13 through recruitment and retention, adherence and a process evaluation.

14

15 **Results:** 40 pwMS (10 men, 30 women, age 44 ± 10 yrs) were randomised and allocated to high
16 (n=19) or low (n=21) flavonoid groups and included in analysis. Missing data was <20% and
17 adherence to intervention of allocated individuals was >75%. There was a small effect on fatigue
18 (Neuro-QoL: effect size {ES} 0.04; confidence interval {CI} -0.40-0.48) and a moderate effect on
19 fatigability (six-minute walk test: ES 0.45; CI -0.18 - 1.07). There were seven adverse events (four
20 control, three intervention), only one of which was possibly related and it was resolved.

21

22 **Conclusion:** A flavonoid beverage demonstrates the potential to improve fatigue and fatigability in
23 RRMS.

24 **Introduction**

25 Ninety percent of people with Multiple Sclerosis (pwMS) experience fatigue [1]. Fatigue and
26 fatigability are difficult to treat and greatly affect health related quality of life in pwMS [2].
27 Fatigability is a term derived from the broader definition of fatigue which refers to an inability to
28 maintain both physical and cognitive performance [3]. The aetiology of fatigue in MS is complex
29 including possible neural, inflammatory, metabolic and psychological mechanisms [2] [4]. Whilst a
30 number of behavioural and drug approaches for fatigue management have been explored, to date the
31 strongest evidence of success in reducing MS related fatigue is from exercise interventions [5] [6].
32 However success is limited and other approaches or combination therapies need to be investigated [7].

33 Dark chocolate containing 70-85% cocoa solids is well known for its high antioxidant and
34 flavonoid content. Over a four week period, dark chocolate consumption has been shown to improve
35 subjective fatigue in those with Chronic Fatigue Syndrome (CFS) [8] [9], and results from a small
36 randomised controlled pilot study using a short-term cocoa intervention suggested an increase in sleep
37 quality and reduction in fatigue [10]. A simple dietary supplement could be implemented alongside
38 other behavioural interventions early after diagnosis as an adjunctive therapeutic approach to support
39 pwMS to manage fatigue. There is currently limited evidence-based guidance to inform tailored
40 dietary advice for symptom management in pwMS. Most diet based studies to date have looked at the
41 risk of development or relapses in MS [11] [12]. However, modifiable lifestyle factors strongly
42 correlate to clinically significant fatigue and remain a target for therapeutic trials [13]. To date there
43 has been limited research assessing the effect of dietary interventions in pwMS [14], but they have
44 identified good adherence to dietary interventions.

45 We propose that a flavonoid approach for managing MS related fatigue may be moderately
46 effective, inexpensive, and safe [15] and that it may be exerting its effects by reducing inflammation
47 and oxidative stress. The aim of the current trial was to evaluate the feasibility and estimate potential
48 effect to inform a follow-on substantive trial. The following key objectives were assessed: 1) The
49 acceptance of the study design and diet intervention by participants; 2) Monitoring recruitment rate
50 and the process of randomisation, adherence to the protocol and loss to follow up; 3) Efficiency of
51 data collection methods; 4) The estimate of effect size for fatigue, fatigability and other measures.

52
53

54 **Methods**

55 This was a parallel, randomised, double-blind placebo-controlled trial to assess feasibility and
56 efficacy (Trial registration ISRCTN: 69897291; Ethical approval National Research Ethics Service
57 {Solihull West Midlands} reference: 199515). Oxford Brookes University acted as sponsor and the
58 study was conducted in accordance with the Declaration of Helsinki.

59

60 *Recruitment*

61 Recruitment was through neurology clinics in the Thames Valley, UK. In addition, local MS Society
62 branches were made aware of the trial and given contact details, and an advertisement for the study
63 along with the participant information sheet (PIS) was made available on the MS Society website.
64 Individuals were able to self-refer to the study by contacting the researchers.

65

66 *Setting*

67 The intervention took place in the home of each participant. All testing took place at Oxford Brookes
68 University (OBU), Oxford, UK except for optional home visits at week 3. Assessments took place
69 between 7.30 and 10 am and the intervention lasted a total of 6 weeks with three testing visits
70 (baseline, week 3 and 6).

71

72 *Randomisation and allocation*

73 After recruitment, participants were allocated the next available study number by the blinded assessor.
74 The study number related to a computer-generated randomisation list held by the principle
75 investigator and randomised individuals (1:1) into the intervention or the control group. The
76 randomisation list used minimisation to balance groups for gender and if individuals were on disease
77 modifying treatments (DMTs) at baseline. The list provided a three digit code that related to a code on
78 identical pre-package sachets (made up by a co-investigator) containing either intervention or control
79 cocoa. The sachets were then dispensed to the participant. The intervention began three days after
80 baseline. Group allocation was concealed throughout the study and analysis.

81

82 *Eligibility*

83 Eligibility criteria were: adults aged ≥ 18 years with a < 10 year clinical diagnosis of RRMS, either
84 treatment naïve or taking first line DMTs (supplementary file 1), no relapse or sudden change in MS
85 symptoms within the previous three months, no contraindications to providing a blood sample or
86 tolerating the cocoa drink, fatigue greater than 4 out of 7 on the Fatigue Severity Scale (FSS) [16],
87 had no other conditions that may be associated with fatigue (e.g. anaemia), not on medication for the
88 treatment of depression, an Expanded Disability Status Scale (EDSS) score of < 4.5 [17], sufficient
89 mental capacity to consent, able to walk with or without a walker for at least 16 meters, no condition
90 affecting the central nervous system other than MS (migraine and headache were allowed), not

91 pregnant or lactating and no objection to the researchers contacting their general practitioner (family
92 doctor) and neurologist.

93

94 *Intervention*

95 Participants were provided with cocoa by the lead researcher at baseline and at week three, and they
96 were asked to consume the drink in their homes daily. Cocoa was consumed after an overnight fast at
97 the same time each morning. After the consumption of the drink, they were instructed to wait 30
98 minutes before consuming any other food or beverage and/ or take their medication. Participants were
99 instructed to take their medication and to follow their usual diet for the rest of the day. The cocoa
100 drinks (intervention and control) were designed to differ only in flavonoid content (low versus high
101 flavonoid; supplementary file 2). Cocoa powder was provided to participants in air tight individual
102 sachets. They were asked to add the sachet content to a mug and to add heated rice milk prior to
103 consuming the drink. Instructions on preparation were provided to ensure all participants followed the
104 same protocol. Unused cocoa powder was collected by the researcher at the next assessment.

105

106 *Outcomes*

107 The primary aim was to assess feasibility of the dietary intervention in terms of recruitment rate and
108 the process of randomisation, adherence to the protocol and loss to follow up, safety and process. We
109 documented adverse events (AEs). Duration of participation and dropout from the intervention were
110 also recorded. Appropriateness of data collection methods was determined through completion of
111 questionnaires and missing data, and through the process evaluation, and estimates of effect {effect
112 sizes (ES) and confidence intervals (CI)} were calculated for the measures and demographics were
113 collected at baseline.

114

115 *Fatigue and fatigability*

116 Throughout the six-week intervention participants were asked to rate their level of fatigue on a
117 numerical rating scale (NRS) through daily ‘fatigue texts’ sent at 10:00, 15:00 and 20:00 every day,
118 rating their fatigue between 1-10 (10 worst). They replied to the text message of ‘*on a scale from 1-
119 10, with 1 being no fatigue and 10 being the worst fatigue you have experienced, how fatigued are
120 you at the current time?*’. They did this at 10 am, 3 pm and 8 pm every day for six weeks. Fatigability
121 was measured at baseline and week 6 using the six minute walk test (6MWT) [18]. Participants were
122 asked to walk at their normal, comfortable walking pace back and forth on a measured 16-metre track
123 in a University corridor. Distance walked was measured. At baseline, week 3 and 6 the levels of
124 subjective fatigue experienced over the past seven days were measured using the Neuro-QOL short
125 form questionnaire [19]. The Adult Memory and Information Processing Battery (AMIPB) [20] was
126 used to measure cognitive fatigue. The AMIPB required the second highest number in each row to be

127 circled, with 15 rows of five double digit numbers. Participants had two minutes and their attempts
128 were timed, with incorrect answers being noted.

129

130 Questionnaires administered at baseline, week 3 and 6 were: the Physical Activity Scale for the
131 Elderly (PASE) [21], EQ5D-5L [22], Preference-Based Multiple Sclerosis Index (PBMSI) [23] and
132 the Hospital Anxiety and Depression Scale (HADS) [24]. Demographic information was collected. A
133 previously published protocol paper gives detail about each measure [25]. Activity was monitored
134 with seven-day wrist worn accelerometers (Axivities ®) prior to, and over two separate weeks of the
135 trial (week 2-3 and 5-6).

136

137 Blood markers of inflammation were measured including: TNF-alpha, reduced glutathione, a marker
138 of antioxidant status and lipid peroxidation.

139

140 Detailed description of measures can be found in supplementary file 1.

141

142 *Process evaluation*

143 Upon exiting the study at week 6, each participant was interviewed about the intervention process,
144 ease of adherence, tolerance and acceptability of the flavonoid drink and the collection of outcome
145 measures. Participants were asked their opinion on the importance of the research question proposed
146 to inform future trials. The thirteen topics used included difficulties with intervention delivery,
147 scheduling of assessments and outcome measure acceptability and suggestions on how to improve the
148 intervention process. A proportion of the data (20%) was coded by two different team members to
149 check on reliability of the coding scheme. Transcripts of interviews were examined to identify themes
150 and categories. Codes were applied to these broad themes, which were then broken down further into
151 sub-codes. Agreement on concepts and coding by blinded assessors were sought between two
152 members of the research team to ensure reliability.

153

154 *Analysis*

155 Feasibility was analysed through evaluation of eligibility, recruitment and retention [26].

156 Completeness of outcome measures was reported and 80% was set as a criterion for success.

157 Retention was measured by the proportion of participants who were lost to follow-up. Successful
158 adherence to the intervention was defined as at least 75% of the participants having completed cocoa
159 consumption. Further aspects of adherence were measured by the percentage of fatigue texts
160 completed by participants.

161 Primary analysis followed the intention to treat principal utilised the complete case data set.

162 Results were presented using point estimates and 95% confidence intervals. For the fatigue texts the
163 fatigue NRS was calculated as the area under the curve (AUC) for each group, ignoring area beneath

164 the baseline, and was calculated geometrically [27]. Data was transformed to improve model fit, or
165 different regression approaches were used (e.g. Negative Binomial, or Poisson regression). The results
166 for the 6MWT are reported as mean \pm SD and for the comparison of baseline and post-intervention as
167 mean difference \pm standard error [(SE); 95% (CI)]. A Linear Mixed Model (LMM) was used to
168 differences between groups throughout all time points. Alternatively and wherever the variables were
169 categorical, such as the EQ5D-5L sub categories, a generalized estimating equation (GEE) with
170 appropriate distributions (e.g. Negative Binomial) method was implemented. Both methods used
171 SAS/STAT 14.3. Fatigue and fatigability measures including the Neuro-QoL short form fatigue, the
172 6MWT and the AMIPB were further analysed to determine difference between responders and non-
173 responders and relative risk scores then calculated. Responders on the NeuroQoL, for both the control
174 and intervention groups, were classified as those who had a clinically meaningful change of 10 points
175 out of 100 (with the questionnaire total score converted from an original total of 40 between baseline
176 and week 6. Responders on the 6MWT were classified as those who had a minimally important
177 change (MIC) in covered distance of 21.6m [27] between baseline and week 6.

178 Data over three time points for activity data was analysed using a Freidman's test and
179 between group effects were calculated using a Mann-Witney test. Process evaluation included
180 frequencies for adhering to the intervention, session content and progression which was analysed
181 descriptively with confidence intervals and regression where possible. A standard content analysis
182 techniques were employed.

183

184 **Results**

185

186

187

188 Between May 2016 and August 2017, 40 pwMS were recruited from four neurology clinics including:
189 Oxford University Hospitals NHS Trust (John Radcliffe Hospital site), Milton Keynes hospital, Royal
190 Berkshire hospital or Buckingham hospital or through advertisements and online media (MS Society
191 webpage and MS Trust Facebook page).

192

193 Figure 1 shows participant flow. It was not possible to determine the total number of people screened.

194

195

196

197 *Feasibility*

198 Fifty-three people showed an initial interest in the trial, but decided not to take part due to: not having
199 enough time to take part in the trial, did not like chocolate, or were unable to take part in nutrition
200 trials due to being on weight loss programs or having gastric surgery. All but one person consumed
201 the cocoa with rice milk (one consumed almond milk). One person discontinued the control
202 intervention but was not lost to follow up and one person consented to be on the trial but decided not
203 to consume the cocoa from the start of the intervention. Adherence to intervention overall was 100%
204 (19/19) for the intervention group and 90% (19/21) for the control group. Missing data from NRS was
205 less than 20% of total responses, but reporting did drop in week 6. Blood measures were only
206 achieved in 20 participants (after a maximum of three attempts). Overall missing data for secondary
207 measures was less than 20%. There were seven AEs during the trial, caused by worsening fatigue,
208 feelings of nausea, or a general feeling of being unwell. AEs were considered unlikely to be related
209 (five), possibly related but expected/ resolved (one) and not related to the intervention (one). Four
210 AEs were associated with the control cocoa and three with the high flavonoid cocoa. There were no
211 incidences of un-blinding of the researcher nor participant. Five out of 40 people were seen at home at
212 week 3.

213 Demographic and clinical data are shown in Table 1. There were no significant differences
214 for demographics between the groups at baseline ($p>0.05$).

215

216

217

218

219

220

221 Table 1. Demographic data

222 Demographic information at baseline for both groups

223		Intervention (n = 19)	Control (n = 21)
224			
225	Age (years)	41 ± 11	46 ± 8
226	Women	14 (74%)	16 (76%)
227			
228	BMI (kg/m ²)	26 ± 7	25 ± 6
229	Treatment naïve	7/19(37%)	6/21(29%)
230			
231	Medications		
232			
233	Anti-depressants/anxiolytic	6	6
234	Anti-convalescents/anti-	3	6
235	spastics		
236	Sedating analgesic	0	1
237	Other sedating	2	7
238	Other (excluding DMTs)	25	24
239			
240	Smokers	0(0%)	2(10%)
241	Uses assistive device	2(11%)	6(29%)
242	Report food allergy	2(11%)	2(10%)
243	Reported food intolerance	6(32%)	5(24%)
244	Reported taking special diet	4(21%)	2(10%)
245			
246	Fatigue Severity Scale (FSS)	5 ± 2	5 ± 3
247	Total		
248			
249	Barthel Index (BI) Total	20 ± 2	19 ± 8
250	Physical Activity for the	90 ± 32	102 ± 31
251	Elderly (PASE) Total		

252

253 Values are means ± standard deviations, or total number of people in () considering the percentage of
 254 the total sample population. FSS and Barthel Index totals are reported as medians ± ranges. An
 255 independent t-test was used to compare means for age, BMI, PASE. A Mann-Witney U test was used
 256 to compare medians for FSS and BI for non-parametric measures to determine differences between

257 the intervention groups. A chi-squared test was used to compare means for nominal data. There were
258 no significant differences between groups for any baseline measures ($p>0.05$).

259 *Outcome measures*

260

261 Between group effect sizes were considered from all three assessments points. Efficacy potential of
262 fatigue and feasibility was determined. A breakdown of the outcome measures is shown in Table 2.

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

Table 2. Results for outcome measures at baseline, week 3 and week 6 of the intervention.^a

	Control Baseline (n=21)	3 weeks	6 weeks	Intervention Baseline (n=20)	3 weeks	6 weeks	Relative risk c	Effect sizes with 95% CI b
Fatigue								
Neuro-QoL	25.86 ± 1.27	22.55 ± 1.18	22.95 ± 1.51	27.63 ± 0.88	24.21 ± 1.21	22.95 ± 1.17	1.45	0.04 (- 0.40-0.48)
Fatigability								
AMIPB								
Incorrect	1 ± 2	1 ± 1	1 ± 2	0 ± 1	0 ± 1	0 ± 1		-0.13 (- 0.34-0.09)
Time	53.83 ± 3.83	55.80 ± 5.00	52.43 ± 3.44	58.85 ± 4.01	57.66 ± 4.07	58.67 ± 4.74		0.11 (- 0.34-0.55)
6 minute walk	344 ± 17.67	n/a	354.5 ± 19.29	360.9 ± 13.15	n/a	394.6 ± 18.11	1.80	0.45 (0.18 - 1.07)
Numerical rating scale fatigue	n/a	35 + 12	34 + 16	n/a	33 + 18	31 + 18		
QoL								
EQ5D-5L								
Mobility	2 ± 3	2 ± 3	1.5 ± 3	1 ± 2	1 ± 2	1 ± 2		-0.02 (- 0.26-0.22)
Self-care	1 ± 2	1 ± 2	1 ± 2	1 ± 1	1 ± 1	1 ± 1		-0.30 (- 0.43— 0.16)
Usual activities	2 ± 3	2 ± 2	2 ± 3	2 ± 2	2 ± 2	2 ± 2		-0.12 (- 0.33-0.11)
Pain/ discomfort	2 ± 3	2 ± 3	2 ± 3	2 ± 3	2 ± 2	2 ± 3		-0.25 (- 0.45— 0.02)
Anxiety/ depression	1 ± 2	1 ± 2	1 ± 2	2 ± 2	2 ± 2	2 ± 2		0.15 (- 0.07-0.36)
Health today VAS	67.71 ± 3.30	68.50 ± 3.98	74.15 ± 3.56	71.58 ± 3.48	71.95 ± 3.25	72.79 ± 3.30		0.24 (- 0.21-0.69)
HADS								
Depression	5 ± 8	4 ± 7	4.5 ± 9	4 ± 5	5 ± 7	5 ± 7		0.09 (- 0.15-0.33)
Anxiety	7.62± 0.74	7.25± 0.70	6.65± 0.80	7.32± 0.83	7.21± 0.83	6.63± 0.82		0.14 (- 0.31-0.58)
PBMSI								
Walking	2 ± 2	2 ± 2	1.5 ± 2	1 ± 2	1 ± 2	1.5 ± 2		-0.15 (- 0.35-0.07)
Fatigue	2 ± 2	2 ± 2	2 ± 2	2 ± 2	2 ± 2	2 ± 2		-0.12 (- 0.29-0.06)
Mood	1 ± 2	1 ± 2	1 ± 2	1 ± 2	1 ± 2	1 ± 2		-0.10 (- 0.30-0.11)
Concentration	2 ± 3	2 ± 2	2 ± 2	2 ± 2	2 ± 2	2 ± 2		0.05 (- 0.15-0.26)
Roles/ responsibility	1 ± 2	1 ± 2	1 ± 2	1 ± 2	1 ± 1	1 ± 2		-0.06 (- 0.25-0.14)
Mechanism								
Plasma								
Lipid peroxidation	0.66 ± 0.01	0.68 ± 0.01	0.67 ± 0.01	0.69 ± 0.01	0.69 ± 0.01	0.70 ± 0.02		0.50 (0- 0.99)
TNF-alpha	0.12 ± 0.01	0.12 ± 0.01	0.10 ± 0.01	0.13 ± 0.01	0.11 ± 0.01	0.11 ± 0.01		0.01 (- 0.22-0.23)
Glutathione	0.0043 ± 0.0047	0.0045 ± 0.0031	0.0035 ± 0.0030	0.0034 ± 0.0051	0.0035 ± 0.0041	0.0060 ± 0.0040		0.07 (- 0.55-0.69)

280
281
282
283

a. Values are means ± SE for normally distributed values and medians ± ranges (1st to 3rd quartile) for categorical data.
b. Effect sizes and CI's are Cohen's d, based on non-central t distributions of least squares means differences for continuous variables, using SAS 9.4 and Cliff's delta, for categorical variables, using R 3.5.
c. Relative risks were calculated for measure of fatigue and fatigability for responders versus non responders.

284 Physical activity levels over the intervention period can be seen in Table 3.

285

286 Table 3. Physical activity levels (reported in minutes per day on average) using an accelerometer
 287 watch prior to the intervention, between 9 to 16 days (3 weeks) into the intervention and between 35
 288 to 42 days(6 weeks) at the end of the intervention, broken down into sedentary light moderate and
 289 vigorous classification.

290

291

	Baseline control	3 weeks	6 weeks	Baseline intervention	3 weeks	6 weeks
Activity	1052.97	1031.17	1049.98±1	1049.20	1090.68±	1064.78
Sedentary	± 23.78	±28.07	9.12	± 29.97	32.06	±22.49
Light	302.48 ± 15.15	304.68 ±17.78	305.16 ±14.22	317.59 ±24.28	293.98 ± 23.53	311.70 ± 18.49
Moderate	83.44 ±13.67	101.76 ± 14.29	82.59 ±10.12	71.78±9.63	76.04±9.64	82.04±9.91
Vigorous	1.67 ±0.69	1.65 ±0.82	1.99 ±1.19	1.98 ±0.93	2.74 ±1.05	1.55±1.07

304

305 Vales are means ± SE. Total activity for each participant was broken down into sedentary, light, moderate and
 306 vigorous and average for all participants in each group, over each 7-day time period.

307

308

309

310 *Fatigue and fatigability*

311 Fatigue was further analysed to determine difference between responders and non-responders. There
 312 was no difference in means between groups ($p>0.05$) yet the Relative Risk (RR) for those who
 313 responded and therefore had improved fatigue in the intervention group (11 out of 19 responders) to
 314 the control group (8 out of 20 responders) was 1.45. The AMIPB was assessed in a similar way with a
 315 change in 1 SD of an improvement in 11.5 seconds considered clinically meaningful. Based on these
 316 criteria only one person improved in the intervention group and no one in the control group and
 317 therefore a RR was not calculated.

318 There was a medium effect size for distance walked in six minutes (0.45 {CI 0.18-1.07})
 319 between the groups with the intervention showing a larger increase in the metres walked in 6 minutes
 320 after the intervention (Table 2). The RR for responders in the intervention group compared to control
 321 was 1.80 in favour of the intervention group.

322

323 *Process evaluation*

324 Both groups had similar positive experiences about the scheduling of the assessments. 13/19 in the
 325 intervention vs 18/20 people in the control indicated no impact of the measurement instruments used
 326 on weekly routine over the six weeks. Similar numbers in both groups identified that the outcome
 327 measures were acceptable. *Randomisation*: Most comments from both groups indicated acceptance
 328 towards the process of randomisation. *Taste*: Similar numbers (8/19 intervention vs 9/20 control)
 329 reported positive comments about the taste of the cocoa. *Procedures and routine of preparing the*

330 *drink*: A few individuals in both groups identified that it was inconvenient to wait for food after drink
331 consumption (4/19 intervention vs 3/20 control), and that the process did not always fit in with their
332 lifestyle e.g., traveling. Other individuals (15/19 intervention vs 17/20 control) identified that they
333 worked it into a routine. *Continuation of consuming the drink*: half of both groups (9/19 intervention
334 vs 11/20 control) said they would continue the drink if offered. A further four people in both groups
335 said they would continue if it was beneficial or if they could implement their own routine.

336

337

338

339

340

341

342

343

344

345

346 **Discussion**

347 PwMS engaged with the dietary intervention, with fatigue and fatigability measures responding more
348 in the intervention group with effect sizes calculated. The current study was shown to be feasible and
349 well received by pwMS, with high adherence to the intervention and excellent data completion. Our
350 study establishes that the use of dietary interventions is feasible and may offer possible long-term
351 benefits to support fatigue management, by improving fatigue and walking endurance. We further
352 propose that considering the possible anti-inflammatory mechanism, flavonoids may be used as an
353 adjunctive approach alongside other therapeutic interventions and suggest the possible benefit of such
354 combined approaches for fatigue management. However further full powered trials would need to be
355 performed.

356 The time post diagnosis was extended from five to ten years in order to recruit to target (n =
357 40). Adherence (>75%), retention and amount of missing data (<80%) were within the acceptable
358 ranges. Most missing data was from the NRS texts over the six weeks which is not surprising as this
359 was the most time-consuming part of the assessment. Completion was still above 80% of total with
360 the first five weeks, with week six showing the most missing data. Mild AEs have previously been
361 reported when consuming high flavonoid cocoa including nausea and vomiting, gastrointestinal
362 disturbances and headaches [28]. The AEs reported in the current trial did not cause any safety
363 concerns and were similar between groups.

364 This is the first study to suggest the potential for fatigability being improved through a
365 6MWT after six weeks of a flavonoid intervention, with a moderate effect size. In the current study
366 the intervention showed a MIC over time with 33.7m (SE: 8.4) in contrast to the control group 10.2m
367 (SE: 9.6). Fatigue correlates with a decrease of physical endurance [29] and walking speed [30] and
368 therefore a treatment targeting fatigue could also improve walking performance. Flavonoid have been
369 found to increase cerebral blood flow by inducing widespread stimulation of brain perfusion, and this
370 could also influence mood, cognitive performance, fatigue perception and ability to perform specific
371 movement tasks [31]. When considering other symptoms, pain was shown to improve in the flavonoid
372 group over the six weeks as measured by the EQ5D-5L with a moderate effect size. The antioxidant
373 properties of flavonoids are thought to lesson neuropathic pain by alleviating oxidative stress and thus
374 reducing neuron damage caused by lipid peroxidation. [32]. We did not measure objective measures
375 of pain in this trial and therefore further research is warranted to explore the pain improvement.
376 Indeed previous research has pointed towards higher motivation in physical activity in pwMS when
377 symptoms such as pain were improved [33]. This may also allow pwMS to become more active and
378 mobile, as noted by the improvements on the 6MWT.

379 The process evaluation revealed that overall the trial was well accepted, with the timing of
380 assessments and the outcome measures being convenient and low burden, respectively and the
381 participants in both groups found the taste of the cocoa enjoyable, or noted it as neither tasty nor
382 unacceptable. In both groups the blinding and randomisation process were accepted, and a majority of

383 pwMS in both groups declared their willingness to continue consuming the cocoa long term,
384 especially if benefits to fatigue were found. However findings around the preparation of the drink and/
385 or scheduling the timing of drink consumption into ones routine are factors to consider for future
386 trials.

387

388 **Limitations**

389 As a feasibility study a powered investigation using a sample size of 80 is now needed. For blood
390 measures, the lack of ability of the phlebotomist to collect blood from several of the participants led to
391 missing data. From the data collected, there were small effect sizes in blood indicators, apart from
392 lipid peroxidation which showed a moderate effect size and therefore this area needs further
393 investigation. The NRS fatigue data was analysed as a total whole change over the six weeks, and
394 therefore more sensitive analysis may have discovered changes within the six weeks. Fatigue may be
395 both physical and cognitive and coexists with and is impacted by a number of factors including
396 anxiety and depression. This study measured a number of these factors including: motor (6MWT) and
397 cognitive (AMIPB) fatigue, and anxiety and depression (HADS) which could be further investigated
398 in a study powered for this. In this pilot we set out to reduce variability from these factors where
399 possible, for example we excluded individuals with a clinical diagnosis or receiving treatment for
400 depression (such as individuals on antidepressants)

401

402 It should be considered that, while we used a wide range of recruitment methods reducing the risk of
403 recruitment bias, participants were recruited from affluent areas of the UK. Acknowledging this
404 limitation, we nevertheless propose the responses in outcome measures are largely generalizable to
405 relatively healthy pwMS.

406

407 **Conclusion**

408

409 The use of dietary approaches to reduce fatigue and associated factors in pwMS may be an easy, safe
410 and cost effect way to impact on quality of life and independence, allowing people to feel more in
411 control of their condition. A full evaluation including wider geography, longer follow up and cost
412 effectiveness is now indicated. This technology has the potential to be implemented in the UK and
413 worldwide, and alongside other rehabilitation including exercise, DMTs and physiotherapy.

414

415 Figure 1 Flow of recruitment legend: The screening and enrolment process for a 6 week randomised
416 double-blind placebo-controlled feasibility trial in people with Multiple Sclerosis. A total of 40 people
417 were included in the final analysis, and reasons for not receiving the allocated intervention (cocoa
418 drink) and discontinuation are presented.

419

420 *Contributorship*

421 Coe, Collett, Soundy, Clegg, Cavey, Wade, Palace, De Luca, Harrison, Buckingham and Dawes were
422 involved in the design and ongoing conduct of the project.

423 Coes and Dawes were responsible for the overall conduct of the project.

424 Coe, Cossington, Soundy, Durkin, Kirsten, and Dawes were responsible for the data collection and
425 day to day running of the trial.

426 Izadi was involved in the statistical analysis of the project.

427 All authors were involved in the writing and proof reading of the project.

428 Wade was responsible for AEs.

429

430 *Trial sponsorship*

431 Oxford Brookes University

432

433 *Funding*

434 Funding for the trial was granted from the Multiple Sclerosis Society; Grant reference 32.

435 Dawes is funded by Elizabeth Casson Trust and Higher Education Thames Valley and the Biomedical
436 Research Centres. Collett is funded by Heath Education Thames Valley.

437 Disclosure funding for highly specialised services to run a national congenital myasthenia service and
438 a neuromyelitis service. Support for scientific meetings and honorariums for advisory work from
439 Merck Serono, Biogen Idec, Novartis, Teva, Abide, Chugai Pharma, Alexion, MedDay, Argenx and
440 Bayer Schering, Medimmune and unrestricted grants from Merck Serono, Novartis, Biogen Idec,
441 Chugai, Alexion and Bayer Schering. MS society and Guthrie Jackson Foundation research grants.

442

443 *Conflict of interest*

444 There was no conflict of interest

445

446 *Ethical approval*

447 Ethical approval was granted from the National Research Ethics Service {Solihull West Midlands}
448 reference: 199515)

449 **References**

450
451

- 452 1. Strober, L.B., *Fatigue in multiple sclerosis: a look at the role of poor sleep*. Front Neurol, 2015. **6**: p. 21.
- 453
- 454 2. Wolkorte, R., D.J. Heersema, and I. Zijdewind, *Muscle Fatigability During a Sustained Index Finger Abduction and Depression Scores Are Associated With Perceived Fatigue in Patients With Relapsing-Remitting Multiple Sclerosis*. Neurorehabil Neural Repair, 2015. **29**(8): p. 796-802.
- 455
- 456
- 457
- 458 3. Kluger, B.M., L.B. Krupp, and R.M. Enoka, *Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy*. Neurology, 2013. **80**(4): p. 409-16.
- 459
- 460 4. Srinivasan, R., et al., *Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T*. Brain, 2005. **128**(Pt 5): p. 1016-25.
- 461
- 462 5. Asano, M. and M.L. Finlayson, *Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication*. Mult Scler Int, 2014. **2014**: p. 798285.
- 463
- 464
- 465 6. Langeskov-Christensen, M., et al., *Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review*. J Neurol Sci, 2017. **373**: p. 307-320.
- 466
- 467
- 468 7. Schwarz, S., et al., *Complementary and alternative medicine for multiple sclerosis*. Mult Scler, 2008. **14**(8): p. 1113-9.
- 469
- 470 8. Sathyapalan, T., et al., *High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome*. Nutr J, 2010. **9**: p. 55.
- 471
- 472 9. Sathyapalan T, C.P., Beckett S, Rigby AS & Atkin SL, *High cocoa polyphenol rich chocolate improves the symptoms of chronic fatigue*. Endocrine Abs, 2006. **6**.
- 473
- 474 10. Coe, S., et al., *Flavonoid rich dark cocoa may improve fatigue in people with multiple sclerosis, yet has no effect on glycaemic response: An exploratory trial*. Clin Nutr ESPEN, 2017. **21**: p. 20-25.
- 475
- 476
- 477 11. Hedstrom, A.K., et al., *High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies*. J Neurol Neurosurg Psychiatry, 2016. **87**(5): p. 454-60.
- 478
- 479
- 480 12. Azary, S., et al., *Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis*. J Neurol Neurosurg Psychiatry, 2018. **89**(1): p. 28-33.
- 481
- 482 13. Weiland, T.J., et al., *Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis recruited via the internet*. PLoS One, 2015. **10**(2): p. e0115541.
- 483
- 484
- 485 14. Bisht, B., et al., *A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue*. J Altern Complement Med, 2014. **20**(5): p. 347-55.
- 486
- 487 15. Yadav, V., L. Shinto, and D. Bourdette, *Complementary and alternative medicine for the treatment of multiple sclerosis*. Expert Rev Clin Immunol, 2010. **6**(3): p. 381-95.
- 488
- 489 16. Herlofson, K., et al., *Fatigue in early Parkinson's disease. Minor inconvenience or major distress?* Eur J Neurol, 2012. **19**(7): p. 963-8.
- 490
- 491 17. Kurtzke, J.F., *Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)*. Neurology, 1983. **33**(11): p. 1444-52.
- 492
- 493 18. Goldman, M.D., R.A. Marrie, and J.A. Cohen, *Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls*. Mult Scler, 2008. **14**(3): p. 383-90.
- 494
- 495 19. Cella, D., et al., *Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology*. Neurology, 2012. **78**(23): p. 1860-7.
- 496
- 497 20. Vlaar, A.M. and D.T. Wade, *The Adult Memory and Information Processing Battery (AMIPB) test of information-processing speed: a study of its reliability and feasibility in patients with multiple sclerosis*. Clin Rehabil, 2003. **17**(4): p. 386-93.
- 498
- 499

- 500 21. Washburn, R.A., et al., *The Physical Activity Scale for the Elderly (PASE): development and*
501 *evaluation*. J Clin Epidemiol, 1993. **46**(2): p. 153-62.
- 502 22. Herdman, M., et al., *Development and preliminary testing of the new five-level version of EQ-*
503 *5D (EQ-5D-5L)*. Qual Life Res, 2011. **20**(10): p. 1727-36.
- 504 23. Kuspinar, A., et al., *Using existing data to identify candidate items for a health state*
505 *classification system in multiple sclerosis*. Qual Life Res, 2014. **23**(5): p. 1445-57.
- 506 24. Zigmond, A.S. and R.P. Snaith, *The hospital anxiety and depression scale*. Acta Psychiatr
507 Scand, 1983. **67**(6): p. 361-70.
- 508 25. Coe, S., et al., *A protocol for a randomised double-blind placebo-controlled feasibility study*
509 *to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to*
510 *reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS)*. Pilot
511 Feasibility Stud, 2018. **4**: p. 35.
- 512 26. Craig, P., *A new CONSORT extension should improve the reporting of randomized pilot and*
513 *feasibility trials*. J Clin Epidemiol, 2017. **84**: p. 30-32.
- 514 27. Cella, M. and T. Chalder, *Measuring fatigue in clinical and community settings*. J Psychosom
515 Res, 2010. **69**(1): p. 17-22.
- 516 28. Crews, W.D., Jr., D.W. Harrison, and J.W. Wright, *A double-blind, placebo-controlled,*
517 *randomized trial of the effects of dark chocolate and cocoa on variables associated with*
518 *neuropsychological functioning and cardiovascular health: clinical findings from a sample of*
519 *healthy, cognitively intact older adults*. Am J Clin Nutr, 2008. **87**(4): p. 872-80.
- 520 29. CRE-2008-0419, *Test-retest Reliability of the StepWatch Activity Monitor Outputs in*
521 *Individuals with Chronic Stroke measure*. Clinical Rehabilitation, 2008.
- 522 30. Huisinga, J.M., et al., *Is there a relationship between fatigue questionnaires and gait*
523 *mechanics in persons with multiple sclerosis?* Arch Phys Med Rehabil, 2011. **92**(10): p.
524 1594-601.
- 525 31. Nehlig, A., *The neuroprotective effects of cocoa flavanol and its influence on cognitive*
526 *performance*. Br J Clin Pharmacol, 2013. **75**(3): p. 716-27.
- 527 32. Azevedo, M.I., et al., *The antioxidant effects of the flavonoids rutin and quercetin inhibit*
528 *oxaliplatin-induced chronic painful peripheral neuropathy*. Mol Pain, 2013. **9**: p. 53.
- 529 33. Fragoso, Y., Santana, DLB, Pinto, RC, *The positive effects of a physical activity program for*
530 *multiple sclerosis patients with fatigue* Neurorehabilitation, 2008. **23**(2): p. 153-57.

531

Figure 1 Flow of recruitment

